CXA-10
CXA-10 is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
62.5%
5 of 8 finished
37.5%
3 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
Oral CXA-10 in Pulmonary Arterial Hypertension
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Anti-Inflammatory Lipid Mediators in Asthma
Clinical Trials (9)
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
Oral CXA-10 in Pulmonary Arterial Hypertension
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Anti-Inflammatory Lipid Mediators in Asthma
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
Oral CXA-10 Study in Healthy Volunteers
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9